2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
70
TL;DR: In 2018, the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions as discussed by the authors .
read more
Abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.
25 Mar 2024
TL;DR: Changing etiology and epidemiology of hepatocellular carcinoma: HCC is primarily caused by HBV infection, but the incidence of HCC related to NASH and NAFLD has increased worldwide.
42
Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association
Yuri Cho,Jin Woo Choi,Hoon Kwon,Kun Yung Kim,Byung Chan Lee,Hee Ho Chu,Dong Hyeon Lee,Gyoung Min Kim,Jung Suk Oh,Dongho Hyun,In Joon Lee,Hyunchul Rhim +11 more
TL;DR: In this article , a group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE.
27
Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and MR imaging.
TL;DR: In this paper , the authors evaluated the prognostic value of microvascular invasion (MVI) classification and analyzed the radiologic features predictive of MVI in hepatocellular carcinoma (HCC) patients.
Radiologic features of hepatocellular carcinoma related to prognosis
Shin Hye Hwang,Hyungjin Rhee +1 more
TL;DR: Examination of imaging findings related to the prognosis of HCC as well as their associated clinicopathological characteristics is reviewed to decide the treatment strategy for HCC.
11
Multidisciplinary approach for hepatocellular carcinoma patients: current evidence and future perspectives
Joo Hyun Oh,Dong Hyun Sinn +1 more
TL;DR: Multidisciplinary approach for HCC management is promising, but lacks robust evidence and requires increased resources.
References
Chemoembolization with Lobaplatin Mixed with Iodized Oil for Unresectable Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation
TL;DR: Lobaplatin-based chemoembolization may elicit effective tumor response for recurrent HCCs and improve the overall survival of patients with unresectable HCC recurrence following OLT.
Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients.
In Joon Lee,Jeong Hoon Lee,Yun Bin Lee,Yoon Jun Kim,Jung Hwan Yoon,Yong Hu Yin,Myungsu Lee,Saebeom Hur,Hyo Cheol Kim,Hwan Jun Jae,Jin Wook Chung +10 more
TL;DR: DB-TACE is followed by significantly shorter PFS than cTACE in patients with nodular HCCs and Child–Pugh class A, although OS is comparable.
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study.
Shigeo Shimose,Hideki Iwamoto,Takashi Niizeki,Tomotake Shirono,Yu Noda,Naoki Kamachi,Shusuke Okamura,Masahito Nakano,Hideya Suga,Ryoko Kuromatsu,Taizo Yamaguchi,Takumi Kawaguchi,Masatoshi Tanaka,Kazunori Noguchi,Hironori Koga,Takuji Torimura +15 more
TL;DR: It is concluded that the appearance of hypertension has potential as an early surrogate marker to predict improved prognosis and careful management to avoid discontinuation of treatment leads to longer survival in patients receiving LEN.
Bridging to liver transplantation in HCC patients.
TL;DR: During the waiting period for LT, patients with HCC at risk for tumour progression and therefore bridging therapy is recommended for patients with an estimated waiting time of ≥6 months.
Role of Biomarkers and Biopsy in Hepatocellular Carcinoma.
Vincent L. Chen,Pratima Sharma +1 more
TL;DR: Sequencing HCC tumors has yielded substantial insights into HCC tumor biology and has raised the possibility of precision oncology in which therapy decisions are guided by cancer genetics, however, it is not ready for prime time yet.
Related Papers (5)
T. Hasegawa,Nobuyuki Takemura,Tatsuya Yamashita,Takeyuki Watadani,Masaki Kaibori,Shoji Kubo,M Shimada,Hiroaki Nagano,Etsuro Hatano,Hiroshi Aikata,Hiroko Iijima,Kazuomi Ueshima,Kazuyoshi Ohkawa,Takuya Genda,Kaoru Tsuchiya,Takuji Torimura,Masafumi Ikeda,Junji Furuse,Masaaki Akahane,Satoshi Kobayashi,Hideyuki Sakurai,Atsuya Takeda,Takamichi Murakami,Utaroh Motosugi,Yutaka Matsuyama,Masatoshi Kudo,Ryosuke Tateishi +26 more